Evidence map›Paper›PMID 36007802›Full record

ReviewAutoimmunity reviews2022

Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series.

Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, Sabrina Rosaria Paparo, Armando Patrizio, Eugenia Balestri, Valeria Mazzi, Laura Gragnani, Clodoveo Ferri, Chiara Botrini and 2 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Autoimmunity reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Thyroid Autoimmunity and SARS-CoV-2 Infection.Journal of clinical medicine · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Poupak FallahiDepartment of Translational Research of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Silvia Martina FerrariDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Giusy EliaDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Sabrina Rosaria PaparoDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Armando PatrizioDepartment of Emergency Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Eugenia BalestriDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Valeria MazziDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Laura GragnaniMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence Center, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Clodoveo FerriRheumatology Unit, University of Modena and Reggio Emilia, School of Medicine, Modena, Italy; Rheumatology Clinic 'Madonna Dello Scoglio' Cotronei, Crotone, Italy.
Chiara BotriniDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Francesca RagusaDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Alessandro AntonelliDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy. Electronic address: alessandro.antonelli@unipi.it.
University of Pisa · ITAzienda Ospedaliera Universitaria Pisana · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the beginning of the pandemic, numerous risk factors have been associated with SARS-CoV-2 infection and COVID-19 outcomes, such as older age, male sex, and the presence of comorbidities, such as hypertension, obesity, and diabetes. Preliminary data also suggest epidemiological association between SARS-CoV-2 infection and systemic autoimmune disease. For this reason, we investigated if patients affected by autoimmune thyroid disorders (AITD) are at risk of developing SARS-CoV-2 infection or COVID-19 disease. From April to September 2020, we have conducted a telephone survey that included 515 consecutive unselected patients with known thyroid disorders, of which 350 were affected by AITD. All 11 definitive diagnosis of COVID-19 (def-sympt-COVID-19) belonged to the AITD group, while the rest 14 cases highly suspected for COVID-19 (suspect-sympt-COVID-19) were equally detected in both group (7 in AITD and 7 in not-AITD). The overall prevalence of symptomatic COVID-19 (def-sympt-COVID-19 + suspect-sympt-COVID-19), recorded in the 350 AITD population was statistically significant higher compared to that reported in the Italian and Tuscan general population at the same time period of the present survey (18/350 = 5.14% vs 516/100000 = 0.51% [p < 0.001; OR = 10.45, 95% CI 6.45-16.92] and vs 394/100000 = 0.39% [p < 0.001; OR = 13.70, 95% CI 8.44-22.25], respectively). Therefore, our results suggest a higher prevalence of SARS-CoV-2 infection and COVID-19 disease in patients with AITD.

Indexed as

COVID-19Hashimoto DiseaseThyroiditis, AutoimmuneAutoimmunityHumansMaleSARS-CoV-2Autoimmune thyroid diseasesChronic lymphocytic thyroiditisCOVID-19Graves' diseaseSARS-CoV-2

Identifiers

PMID36007802
PMCPMC9395221
OpenAlexW4292966239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.